Taliaz Diagnositcs, a Finalist in the 2016 mHealth Israel Startup Contest, is a leader in the field of genetic-based personalized medicine, through the development of genetic-based diagnostic tools that increase efficiency, efficacy and accuracy of medications. The first product enables clinicians to prescribe the most suitable antidepressant medication for each patient.

1. Our Vision
Taliaz Diagnostics will have a meaningful role in the field
of genetic-based personalized medicine, through the
development of genetic-based diagnostic tools that increase
efficiency, efficacy and accuracy of medications.
Our Antidepressant Predictive Tool
Taliaz Diagnostics’ first product is a tested and validated
tool, developed to guide clinicians in prescribing the most
suitable antidepressant medication for each patient.
Our Unique Solution
Our tool guides clinicians to match drugs more accurately to
individual patients. By combining our expertise in genetics
& strong clinical knowledge together with our machine
learning algorithm expertise we have generated a unique
solution which increases treatment success rates to 70%.
Our algorithm analyzes the patient’s DNA sequence and
clinical background to determine the best treatment. We
analyze 180 distinct genetic alterations, compared to the
conventional 15 alterations explored by existing methods.
Using this information, we can predict the medication
the patient will best respond to and the severity of its
side effects. We then recommend the most suitable
antidepressant medication and dosage that presents the
least side effects.
Our tool is the only one to be tested and validated using
the largest existing dataset of patients’ response to a range
of antidepressants, obtained from the NIH.
The Need
In the US, five million patients start treatment for
depression each year. There are dozens of antidepressant
medications on the market today, and patients respond
differently to each. While only 39% of patients recover
after the first treatment, typical treatment is conducted
for months by trial and error process.
There is a clear need for a decision support tool
which would allow the physician to make an
educated decision when matching a treatment to
each patient.

2. Mobile: +972-(0)53-8223951, TeleFax: +972-(0)77-3352506, Email: dekel@taliazdx.com
2 Prof. Yehezkel Kaufmann Street, Tel-Aviv, Textile Center, 17th Floor, post-code 6801294
www.taliazdiagnostics.com
The Market
The application of our platform in the field of psychiatric
disorders alone has tremendous market potential. 1 in 10
adults take antidepressant medications in the US. Major
Depressive Disorder remains the leading cause of disability
among people aged 15-44. Depression is estimated to cost
the US economy over $80 billion each year.
In this environment Taliaz Diagnostics expects to reach sales
of a million test kits annually in the US. This forecast does
not include the European, Indian and Israeli markets we
are currently exploring.
The Team
With years of experience in the areas of bioinformatics and neuroscience, our team generates high-quality research and
develops innovative and practical products. Our unique combination of deep machine learning skills, neuroscience and
genome expertise sets us apart and provides us with the necessary capacities to have an impact in our target market.
These strengths are supported by the right mix of strategy, operations and business skill sets to drive Taliaz Diagnostics
towards reaching its short and long-term business goals.
1 million test
kits annually
Dr. Dekel Taliaz, PhD
CTO & Co-founder
Experimental neuroscientist. Expert in
using molecular methods to manipulate
gene expression to determining genetic
factors which underlie psychiatric
disorders.
Oren Taliaz
CEO & Co-founder
Experienced CEO with critical skills in
driving mission and strategy, budget
and investment management. Founder
of a successful capital markets firm
specializing in foreign currency.
Dr. Zohar Barnet Itzhaki, PhD
VP R&D
Bioinformatician with over 10 years
of experience in academia and private
sector. Expert in the statistical analysis of
genetic variations and in the development
of machine learning algorithms.
Prof. Bernard Lerer, MD
Biological Psychiatry Specialist
World renowned psychiatrist and researcher.
Head and founder of the Biological
Psychiatry laboratory at Hadassah-Hebrew
University Medical Center. Expert in
understanding the role of genetic factors
in response to psychiatric drugs.
Brian Steinberger
VP Business Development
Seasoned business executive with extensive
expertise in operations management and
and business development, overseeing
cross-regional expansions, strategy design
& implementation for global provider of
algorithmic platforms.
Dr. Ran Barzilay, MD, PhD
VP Clinical Studies
Psychiatric neuroscientist. Resident
psychiatrist with experience in basic and
translational neuroscience with a focus
on stress related disorders.